Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass

Bernard Portha, Cécile Tourrel-Cuzin, and Jamileh Movassat

Laboratoire B2PE (Biologie et Pathologie du Pancréas Endocrine), Unité BFA (Biologie Fonctionnelle et Adaptive), Équipe 1, Université Paris-Diderot et CNRS EAC 4413, Bâtiment BUFFON, 5ème étage, pièce 552A, 4, Rue Lagroua Weill Hallé, Case 7126, 75205 Paris Cedex 13, France

Correspondence should be addressed to Bernard Portha, portha@univ-paris-diderot.fr

Received 30 December 2010; Accepted 25 February 2011

Academic Editor: Matteo Monami

Copyright © 2011 Bernard Portha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as enhanced beta-cell proliferation and neogenesis and promotion of beta-cell survival. These effects have tremendous implication in the treatment of T2D because they directly address one of the basic defects in T2D, that is, beta-cell failure. In human diabetes, however, evidence that the GLP-1-based drugs alter the course of beta-cell function remains to be found. Several questions surrounding the risks and benefits of GLP-1-based therapy for the diabetic beta-cell mass are discussed in this review and require further investigation.

1. The Rationale for Restoration of Beta-Cell Mass in Diabetic Patients

Both type 1 and type 2 diabetes are characterised by deficits in beta-cell mass (∼99% deficit in long-standing type 1 diabetes, ∼65% deficit in long-standing type 2 diabetes [1]). There is little doubt regarding the importance of increased autoimmune-mediated beta-cell death in type 1 diabetes, and recent studies in type 2 diabetes suggest that the frequency of beta-cell apoptosis is also significantly increased, although other factors cannot be excluded, such as the failure of beta-cell mass to expand adequately in response to rising secretory demands by adapting beta-cell replication and neogenesis. Loss of beta-cells in both types of diabetes implies that restoration of endogenous insulin secretion and normalisation of hyperglycemia in such patients might be accomplished through the supplementation of islet cells. Indeed, hyperglycemia in both types of diabetes is reversed by pancreas transplantation, and intraportal transplantation of isolated islets temporarily restores glucose control. Unfortunately, replacement of beta-cell mass by islet or pancreas transplantation is associated with both surgical morbidity and the adverse effects of chronic immunosuppression. Some of the risks and side effects, including ischemic and enzymatic damage caused by the islet isolation and purification protocol as well as the concerns of thrombosis and portal hypertension induced by transplanting islets into the liver portal vein, are intrinsic to the islet transplantation procedure itself [2]. Moreover, there is an insufficient supply of pancreases available for the increasing number of people with diabetes, thus preventing the widespread implementation of this intervention. There is, therefore, a need for alternative approaches for restoring functional beta-cell mass in patients with diabetes.

Conceivable approaches to achieve beta-cell supplementation consist of restoring an endogenous source and/or implanting an autologous- or nonautologous-derived source. At present, there are different strategies under investigation: (1) transplantation of beta cells generated in vitro from nonautologous embryonic stem cells, (2) transplantation of beta-cells generated in vitro from patient’s own adult stem cells, and (3) stimulation of beta-cell regeneration in vivo from patient’s own endogenous cell sources.

An alternative strategy for the restoration of beta-cell mass in patients with diabetes is to foster in vivo beta-cell regeneration from patient’s endogenous cell sources. There is
now evidence that beta-cell mass is dynamic and capable of undergoing adaptive changes in response to different secretory demands. In humans, beta-cell mass increases by ~50% in obesity, and both insulin secretion and beta-cell mass have been shown to increase in pregnant women [3]. Likewise, beta-cell mass in rodents increases by ~2.5-fold towards the end of pregnancy and is rapidly decreased through increased apoptosis and reduced replication postpartum. In humans, the overall capacity for beta-cell replication is much lower than in rodents, and very few replicating beta cells (one cell in ~50 islets of ~100 beta-cells each per cross-section) can be found in adult human pancreas [1]. There is, however, a capacity for increased beta-cell replication in humans: beta-cell replication has been reported to be more than ten times higher in human pancreas adjacent to gastrin-producing tumours [4] and in the pancreas of an old patient with recent-onset type 1 diabetes [5]. Indeed, the emerging understanding of beta-cell growth in the adult, either from precursor cells found in the pancreatic ducts or from residual beta cells, holds the promise of developing new strategies for stimulating beta-cell regeneration. Such approach necessitates the delivery of appropriate growth factors to these cells to obtain a full beta-cell phenotype. GLP-1 could be one of the most promising candidates for doing so. The following sections review our current understanding of the therapeutic potential of the GLP-1 receptor (GLP-1R) agonists for the diabetic beta-cell population.

2. Activation of the GLP-1R Signalling Pathway and Beta-Cell Functions

GLP-1 replenishes beta-cell insulin stores via increased insulin mRNA stability, gene transcription, and biosynthesis. It stabilizes mRNA encoding proproinsulin, thereby stabilizing and upregulating its expression [6, 7]. GLP-1 increases insulin gene transcription and biosynthesis via activation of both PKA-dependent and -independent signalling pathways. PDX-1, the most extensively studied insulin transcription factor, is a key effector for the GLP-1R signaling pathway on insulin gene transcription and biosynthesis, as well as differentiation, proliferation, and survival of the beta cell. GLP-1 has been shown, both in vitro and in vivo, to be involved in regulation of PDX-1 by increasing its total protein levels, and its translocation to the nucleus, followed by its binding to the A-box element and the GG2 element of the rat and human insulin promoters and resultant increase in activity of the insulin gene promoter in beta cells [8–13]. The regulation of PDX-1 by GLP-1 mainly occurs via cAMP/PKA-dependent signaling pathway [10]. Nevertheless, GLP-1 triggers expression and nuclear localization of PDX-1 involves the phosphorylation of FoxO1 via transactivation of the EGFR and PI-3K/PKB pathway, resulting in deactivation and nuclear exclusion of FoxO1 and consequent disinhibition of Foxa2-dependent pdx-1 gene promoter activity [14, 15]. In addition, FoxO1 and PDX-1 mutually exclude each other from the nucleus of the beta cell [14]. The GLP-1R signaling pathway also mediates insulin gene transcription via basic region-leucine zipper transcription factors that are related structurally to the transcription factor CREB, and these directly bind to CRE sites on the insulin gene promoter. This effect is independent of Gsa, cAMP/PKA, and PKC and may be mediated by the 90-kDa ribosomal S6 kinase and mitogen- and stress-activated protein kinase family of CREB kinases [16, 17].

GLP-1 is one of the most potent substances known to stimulate glucose-induced insulin secretion (GIIS), and its stimulatory activity is exerted via binding to its receptor on beta cells. This binding results in activation of adenyl cyclase with consequent production of cAMP and subsequent activation of PKA and the Epac family. GLP-1-mediated activation of PKA results in phosphorylation of the SUR1 KATP channel subunit via an ADP-dependent mechanism, facilitating its closure [18]. This is followed by membrane depolarization and triggering of the insulin secretory pathway. Treatment with the PKA inhibitor 8-bromoadenosine-3’,5’-cylic mono-phosphorothioate, Rp-isomer [19], or H89 [18] abolishes GLP-1-induced inhibition of the KATP channels. SUR1 (−/−) islets lack an insulin secretory response but exhibit a normal rise in cAMP to GLP-1, implicating cAMP-dependent PKA-independent signal transduction pathway [20, 21]. It is now clear that the action of cAMP produced by GLP-1 signaling is mediated not just by PKA, but also by Epac2 [22, 23], and Epac2 also inhibits the function of KATP channels in rodent and human beta-cells via interaction with SUR1 [24, 25]. A recent study has also demonstrated that the scaffold protein, β-arrestin-1, facilitates GLP-1-stimulated cAMP production via interaction with GLP-1R [26]. GLP-1 signaling also antagonizes voltage-dependent K+ (Kv) channels via cAMP/PKA-dependent pathway in beta cells, which prevents beta-cell repolarization by reducing Kv currents [27]. However, MacDonald et al., [27] identified a role of PI-3K with subsequent activation of PKCζ in the antagonism of the Kv current by GLP-1. This occurred via epidermal growth factor receptor (EGFR) transactivation, not via the G protein-regulated isofrom p110y [27]. L-type Ca2+ channels are also phosphorylated by PKA, leading to increase of their open probability and enhancement of Ca2+ influx [28–30]. Activation of GLP-1R also increases intracellular Ca2+ through Ca2+-release from the endoplasmic reticulum via the inositol 1,4,5 triphosphate receptors activated by PKA and the ryanodine receptors activated by Epac2 [31, 32]. A recent study has indicated that GLP-1 elevates intracellular Ca2+ concentration via stimulation of the nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose production [33], catalyzed by cyclic ADP-ribose cyclases, that stimulates glucose-induced Ca2+ mobilization [34]. Direct effects of GLP-1 signaling on insulin-containing vesicles have also been described. Lester et al. [35] proposed a mechanism by which changes in insulin secretion are associated with phosphorylation of the vesicle-associated protein synapsin-1 by PKA followed by dephosphorylation by calcineurin [35]. PKA may also regulate the vesicle priming through the phosphorylation of RIM proteins [36]. It is known that RIM proteins bind Rab3a, which serves to tether the vesicle to the plasma membrane [37] and also bind Munc13-1 to create a link between synaptic vesicle tethering and priming [38]. RIM proteins also bind Epac2, and this binding participates
in the regulation of docking and fusion of insulin-containing vesicles to the plasma membrane [39, 40]. In addition, Epac2 interacts with Picollo, a RIM2-interacting protein on insulin-containing vesicles, in a Ca^{2+}-dependent manner [41].

Intracellular cAMP levels have long been recognized to be critical for normal GIIS (glucose-competence) [42]. Thus, receptors linked to cAMP production, such as the GLP-1R play an important role to control cellular cAMP levels. It has been very recently proposed that the biological process regulated by GLP-1 to control the beta-cell glucose competence was dependent on the level of IGF-1R expression and on IGF-2 secretion [43]. Finally, since GLP-1 also stimulates the expression of GLUT2 transporters and glucokinase, which determine the rate of glycolysis, it helps to confer glucose competence to beta cells and thereby increase the efficacy (maximal effect) and potency (threshold concentration) of glucose as a stimulus for insulin secretion [44]. However, this interpretation is questionable in the light of recent extensive data indicating that GLP-1 barely affects beta-cell intermediary metabolism and that metabolic signalling does not significantly contribute to GLP-1 potentiation of GIIS [45].

3. Pharmacological Activation of the GLP-1R Signalling Pathway in Glucose-Insensitive Diabetic Beta Cells

Enhancement of GIIS from the beta cell is one of principal goals for treatment of patients with T2D. Because the mechanism underlying the insulinotrophic action of GLP-1 in an in vitro model of glucose-unresponsive beta cells (dispersed rat beta cells) has been shown to involve activation of adenylate cyclase and cAMP production [42], we investigated the effect of GLP-1 stimulation on cAMP production and GIIS in GK/Par rats with spontaneous T2D [46]. Diabetic GK/Par islets were able to amplify their cAMP content in response to GLP-1 in the presence of high glucose, and this was associated with a strong insulin release with restitution of their insulin secretory competence to glucose [47]. GLP-1-stimulated cAMP generation was instrumental in the GLP-1-triggered insulin release at high glucose since insulin release became no longer reactive to GLP-1 when AC isoforms were acutely blocked by the AC blocker dd-Ado. Since we became no longer reactive to GLP-1 when AC isoforms triggered insulin release at high glucose since insulin release stimulated cAMP generation was instrumental in the GLP-1–associated with a strong insulin release with restitution of GIIS in the presence of high glucose, and this was dependent on the level of IGF-1R expression and on IGF-2 secretion [43].

Furthermore, we report that GLP-1 also normalizes GIIS in islets from n-STZ rats (another recognized model of rat diabetes with glucose-unresponsive beta cells) [48]. This suggests that restoration by GLP-1 of glucose responsiveness in the diabetic beta cell is not restricted to the GK model, but is probably a more generalized mechanism.

4. Activation of the GLP-1R Signalling Pathway and Beta-Cell Growth/Survival

Repair or expansion of the beta-cell population can be achieved through stimulation of beta-cell proliferation and/or neogenesis, and slowing the rate of beta-cell apoptosis. Abundant in vitro and in vivo studies have shown that GLP-1, and its analogs such as Exendin-4 (Ex-4) are capable of inducing beta-cell proliferation in normal rodent islets and insulinoma cell lines [49–52]. This proliferative seems to involve the activation of immediate early genes such as c-jun, junD, nur77, and c-fos [53], and the implication of different intermediary signaling molecules such as PI3K, PKB/Akt, and PKCζ [53, 54]. Studies in INS-1 cells have also indicated that betacellulin-(BTC-) mediated transactivation of the epidermal growth factor receptor/erb-B1 is a prerequisite for GLP-1-induced proliferative effects in these cells [49]. However, BTC failed to induce proliferation in a different insulinoma cell line, RINm5F and also in fetal human beta cells [55]. The importance of the Pdx1 transcription factor in mediating the proliferative effects of GLP-1 in beta cells was demonstrated using mice with beta cell-specific inactivation of the Pdx1 gene. Ex-4-mediated proliferation was blocked in isolated islets from these mice, suggesting that Pdx1 expression is essential for Ex-4-induced proliferative effects [51]. Interestingly, Ex-4 induces Pdx1 expression in human fetal islet cell cultures and promotes functional maturation and proliferation of human islet cell cultures transplanted under the rat kidney capsule [56]. It has become clear that GLP-1 acts by means of Gsx and PI-3K/PKB to stimulate beta cell proliferation and survival. A beta-cell-specific Gsx deficiency in mice results in diabetes characterized by reduced insulin secretion and beta-cell mass with the primary defect being in decreased beta-cell proliferative capacity [57]. It has been also shown that GLP-1 inhibits FoxO1 transcriptional activity through phosphorylation-dependent nuclear exclusion in beta cells [15], and the ability of Ex-4 to increase beta-cell mass was blunted in transgenic mice expressing constitutively nuclear FoxO1 in beta cells [15]. FoxO1 inactivation plays an important role in the effect of GLP-1 on the expression of the two important transcription factors PDX-1 and Foxa2 [16]. GLP-1 activation of PI-3K/PKB facilitates acute nuclear translocation of existing PDX-1. Indeed, mice with a beta-cell-specific inactivation of PDX-1 do not display a proliferative response to Ex-4 treatment [51]. GLP-1 activation of PI-3K is mediated by transactivation of EGF receptors via GLP-1R-mediated activation of c-Src that in turn activates a membrane-bound metalloproteinase, with concomitant release of the soluble ligand BTC which is an agonist of EGFRs [49]. This is also followed by activation and translocation to the nucleus of PKCζ, resulting in enhancement of the stimulatory effect of GLP-1 on beta-cell proliferation [53]. GLP-1 also exerts its stimulatory effects on beta-cell proliferation through CREB-mediated Irs2 gene expression, leading to activation of PI-3K/PKB [58]. GLP-1R activation has been shown to upregulate the expression of cyclin D1 [59, 60], and this effect is likely to be mediated by PKA-dependent activation of CREB [60, 61]. A recent study showed that GLP-1R signaling via cAMP/PAK activates β-catenin/T-cell factor-like 2- (TCF7L2-) dependent Wnt signaling in the proliferation through upregulation of cyclin D1 [62]. A prominent role for β-cateninTCF7L2-dependent Wnt signaling is now acknowledged after the reports that GSK-3β overexpression in mice
induces beta cell mass restriction and the development of diabetes [63], that genetic disruption of GSK-3β in beta-cells results in increased beta-cell mass and that beta-cell regeneration can be promoted by systemic administration of GSK-3β inhibitors to streptozotocin-induced neonatal diabetic rats [64]. Unexpectedly, the proliferative effect of GLP-1 was recently related to IGF-1R expression and autocrine secretion of IGF-2 by the beta-cell, since this effect was suppressed by Igf-1r gene inactivation and by IGF-2 immunoneutralization or knockdown [43].

GLP-1R activation reduces beta-cell apoptosis in purified rodent and human islets as well as beta-cell lines after exposure to many cytotoxic agents, including reactive oxygen species, glucose, free fatty acid, palmitate, cytokines, tumor necrosis factor-α (TNF-α), immunosuppressive reagents, and dexamethasone [66]. A role for endogenous GLP-1 in prevention of beta-cell death was demonstrated by the increased susceptibility to streptozotocin-induced apoptosis in GLP-1R knockout mice; conversely, streptozotocin-induced apoptosis was significantly reduced by coadministration of Ex-4 [67]. Ex-4 also reduces biochemical markers of islet ER stress in vivo and ER stress-associated beta-cell death in a PKA-dependent manner [68, 69]. Similar to GLP-1-induced beta-cell proliferation, antiapoptotic effects of GLP-1 in beta cells are mediated by promotion of FoxO1 nuclear exclusion and consequent upregulation of PDX-1 and Foxa2 expression via EGFR- and PI3K-dependent activation of PKB and cAMP/PKA-dependent activation of CREB, leading to upregulation of IRS2 protein expression and activation of PKB. Also similar to the induction of proliferation, activation of IGF-1 receptor expression and IGF-2 secretion participate to the GLP-1-induced the protection of the beta cells against cytokine-induced apoptosis, through [43]. The protective effect of GLP-1 on beta-cell glucomlipotoxicity is also mediated by PKB activation and possibly its downstream target nuclear factor-κB [70]. In addition, recent studies suggest that GLP-1R agonists protect beta cells from proinflammatory cytokine-induced apoptosis by inhibiting the c-Jun NH2-terminal kinase pathway via upregulation of islet-brain 1, a potent blocker of the c-Jun NH2-terminal kinase pathway [71], and activation of the extracellular signal-regulated kinase 1/2-dependent pathway [72].

GLP-1R was confirmed to be present in pancreatic ducts in mouse, rat, and human [73, 74]. GLP-1R exists in the AR42J acinar cell line derived from a rat pancreatic tumor and treatment with GLP-1 or Ex-4 causes increases in both intracellular cAMP and Ca2+ levels [75]. Activation of GLP-1R signaling either in ductal or acinar cell lines or in vivo in rodents has resulted in differentiation of a fraction of these cells toward an islet-like phenotype, in association with activation of PKC and MAPK, and transcription factors necessary for an endocrine phenotype such as PDX-1, as well as the glucose-sensing factors glucokinase and GLUT2 [76]. GLP-1R activation of those cells also affects transforming growth factor-β signaling pathways, resulting in reduced Smad activity [77, 78]. AR42J cells, even without GLP-1R activation, have the potential to be converted into endocrine [79] but are negative for islet hormones and their transcripts under usual culture conditions [76]. When these cells were exposed to GLP-1 or Ex-4, approximately 20% of the cells contained insulin protein and were capable of releasing insulin in a glucose-mediated mode [76]. Such GLP-1 effect was also observed in Capan-1 cell line [80] and rat ARIP and human PANC-1 cell lines. Similar to the AR42J cells, GLUT2 and glucokinase transcripts were induced in these cell lines [81]. In particular, the differentiation-promoting activity of GLP-1 requires the expression of PDX-1, because PANC-1 cells, which lack endogenous PDX-1, differentiate only when transfected with PDX-1, whereas rat ARIP cells that express PDX-1 are susceptible to undergoing differentiation into insulin-secreting cells [81]. In the Capan-1 cell line, differentiation to insulin-producing cells was also seen when they were transfected with PDX-1, and PDX-1 antisense totally inhibited such conversion [80]. In human pancreatic ducts also where GLP-1 receptor is abundantly expressed, Ex-4 treatment in vitro increases the number of insulin-producing cells. This suggests that GLP-1/Ex-4 is useful to facilitate beta-cell neogenesis in adult pancreatic ducts [74].

5. Pharmacological Activation of the GLP-1R Signalling Pathway in Models of Deficient Beta-Cell Mass

Acute or chronic treatment of diabetic rodents with GLP-1R agonists stimulates beta-cell proliferation and neogenesis and slows the rate of beta-cell apoptosis, leading to an expansion of beta-cell mass. In vivo administration of GLP-1, Ex-4 or other degradation-resistant analogs has been shown to increase beta-cell mass in different prediabetic and diabetic rodent models [11, 65, 82–86]. Administration of GLP-1 or Ex-4 for several days resulted in stimulated expansion of beta-cell mass and increased beta-cell proliferation in old glucose-intolerant rats [84], adult db/db mice, Zucker rats, pancreatectomized rats and mice, or intrauterine growth-retarded rats [87]. A transient treatment of GLP-1 or Ex-4 in STZ-treated newborn rats resulted in a sustained improvement of beta-cell mass through increased beta-cell neogenesis and replication [83] (Figure 1). We obtained similar conclusion in the nSTZ model after in vivo administration of a DPPIV inhibitor (Figure 2). Moreover, diabetic Lepdb/Lepdb mice treated with Ex-4 for 2 weeks showed enhanced expression of PDX-1 in the ducts (favoring the presence of GLP-1R in ductal cells, as referenced above) and the exocrine tissue [11], which means that GLP-1R agonists aid in islet neogenesis, because ductal cells have been thought to be the main source for endocrine neogenesis [88].

Taking advantage of the GK/Par rat model of spontaneous T2D, we have raised the question of what is the impact of GLP-1 or Ex-4 treatment, in terms of beta-cell mass enlargement and long-term improvement of glucose homeostasis. To address this issue, we investigated the ability of GLP-1 or Ex-4 treatment to promote beta-cell proliferation in young GK/Par rats during the prediabetic stage and thereby to prevent the pathological progression of the T2D when animals become adults. GK/Par rats were submitted to GLP-1 or Ex-4 injection from postnatal day 2 to day 6 only [84]. Both treatments enhanced, on day 7, pancreatic
Figure 1: GLP-1 or Exendin-4 (Ex-4) activates beta-cells regeneration in vivo. The aim was to investigate in the rat model of neonatal beta-cell regeneration (nSTZ model), the capacity of in vivo treatments with GLP-1 or Ex-4 to promote beta-cell regeneration. To this end, nSTZ rats from the Wistar strain (W) were submitted to GLP-1 or Ex-4 administration from postnatal day 2 to day 6 only, and their beta-cell masses were tested on day 7 (a) and (b). In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, total beta-cell masses per pancreas were both significantly increased (**P<.001) as compared with values in untreated nSTZ rats, representing, respectively, 51% and 71% of the control Wistar beta-cell mass, while nSTZ beta-cell mass represented only 21% of the control Wistar value. Beta-cell BrdU labeling index (c) in the untreated nSTZ rats was found to be significantly increased (P<.001) as compared with Wistar group. In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, it was similarly increased. A representative figure is given with double immunostaining for BrdU and insulin in 7-day-old nSTZ rats (magnification ×1000). To estimate activation of neogenesis (d) and (e), the number of single beta-cells incorporated into the duct epithelium and the number of beta-cell clusters budding from ducts were quantified. The number of isolated beta-cell within pancreatic tissue of nSTZ rats represented 185% of Wistar value and the number of beta-cell buds in pancreatic tissue in nSTZ rats represented 106% of Wistar value. These two parameters were strongly increased in nSTZ/GLP-1 and nSTZ/Ex-4 rats as compared to untreated nSTZ rats (**P<.001). A representative figure is given with indirect immunoperoxidase staining for insulin in 7 day-old nSTZ/GLP-1 rats (magnification ×1000). Adapted from Tournel et al. [83].
insulin contents and total beta-cell mass by stimulating both beta-cell neogenesis and beta-cell regeneration. Followup of biological characteristics from day 7 to adult age (2 months) showed that both treatment exerted long-term favorable influence on beta-cell mass and glycemic control at adult age. As compared to untreated GK/Par rats, 2-month-old GLP-1 or Ex-4-treated GK rats exhibited improved glucose-stimulated insulin secretion, in vivo after intravenous glucose load or in vitro using isolated perfused pancreas. Moreover, plasma glucose disappearance rate was increased in both treated GK/Par groups compared to untreated GK/Par group [84]. These findings model indicate that a GLP-1 or Ex-4 treatment limited to the prediabetic period, delays the installation, and limits the severity of T2D in the GK/Par model.

GLP-1R activation also promotes preservation and expansion of beta-cell mass in type 2 diabetic rodent models through protecting beta cells against the deleterious effects of the diabetic milieu (i.e., increased cytokine toxicity, glucose toxicity, and lipotoxicity). Ex-4 treatment of Lepdb/Lepdb mice decreases activation of caspase-3 and prevents beta-cell apoptosis through PKB and MAPK [85] and infusion with GLP-1 drastically reduced the number of apoptotic beta cells in islets of Zucker diabetic rats [65].

Collectively, the studies above mentioned so far indicate that GLP-1R agonists may prove useful for expansion of human beta cells either cultured in vitro, after transplantation, or after sustained treatment of diabetic subjects in vivo.

6. Current Issues That Challenge the Beneficial Effects of GLP-1R Agonists for Beta-Cell Therapy

6.1. Risk of Pancreatic Tumor Formation in Patients Receiving GLP-1R Agonist Supplementation. If GLP-1R agonists were to be used continuously to treat diabetes, then uncontrolled beta-cell proliferation would become an issue unless there were brakes on the system. Klinger et al. [89] shed light on cellular mechanisms that may indeed limit the proliferative effect of GLP-1 in beta-cells: GLP-1 provides its own brakes because it leads to the rapid and strong expression of four negative regulators of intracellular signalling: RGS2 (regulator of G protein signalling 2), Dusp14 (dual-specificity phosphatase 14, also called MAP kinase phosphatase 6, a negative feedback regulator of the mitogen-activated protein kinase signaling cascade), Icer (inducible cAMP early repres- sor), and Crem-α (cAMP responsive element modulator alpha). However, an obvious question to be further studied is whether unrestrained beta-cell proliferation may result from loosening of the GLP-1 effect upon these negative regulators of beta-cell growth, during long-term treatment.
6.2. Risk of Pancreatitis in Patients Receiving GLP-1R Agonist Supplementation. Another concern with respect to clinical use of GLP-1 relates to reports of pancreatitis in some patients long-term treated with long-acting GLP-1 receptor agonists [90]. However, amylase levels and pancreatic markers of inflammation were found reduced in Ex-4-treated mice, and Ex-4 did not increase the severity of pancreatitis in a murine model of this condition [91]. Furthermore, no evidence was found for an increased incidence of pancreatitis in a large cohort of patients treated with either exenatide or sitagliptin, compared with those treated with metformin or glyburide [92]. Notwithstanding, a recent paper in the HIP diabetic rat model treated with sitagliptin has reported ductal hyperplasia in all sitagliptin-treated animals, acinar to ductal metaplasia in some, and haemorrhagic pancreatitis in one isolated case [93]. Histologic evidence of pancreatic acinar inflammation has also been found in rats treated with Ex-4 and their acinar cells were abnormal in appearance and had a greater frequency of cell death [94]. Pancreatic ductal replication is increased in humans with obesity and/or type 2 diabetes [95], providing a possible link between the increased risk of pancreatitis in individuals with obesity and/or T2D. In common with the HIP rat model of diabetes, pancreatic ductal replication was also increased in humans with obesity and T2D [95]. The mechanisms that induce increased pancreatic ductal replication in patients with obesity and/or type 2 diabetes are unknown. Excessive fat accumulation in pancreas could induce local inflammation [95]. Increased beta cell apoptosis in type 2 diabetes is also associated with inflammation and increased local cytokines [96]. Such combination might activate islet regeneration via duct-related progenitors, comparable to the process proposed for acinar tissue in chronic pancreatitis. GLP-1 therapy may potentially amplify ductal hyperplasia since it has been reported to activate pancreatic regenerative efforts with increased duct cells positive for PDX-1 [74]. Given the clinical gravity of pancreatitis, a better understanding of this issue is important.

6.3. Relevance of GLP-1R Agonist Supplementation for T1D. Although regenerative and antiapoptotic actions of GLP-1 or Ex-4 have been demonstrated in both normoglycemic and diabetic animal models, the majority of these studies were conducted in animal models of T2D [83–87]. In contrast, much less is known about whether the actions of GLP-1R agonists are maintained in the setting of an ongoing autoimmune attack, as is the case in the NOD mouse, the BB rat, and in human subjects with type 1 diabetes (T1D). Zhang et al. [97] have shown that continuous delivery of GLP-1 via an osmotic minipump in prediabetic NOD mice results in significant increases in beta-cell mass and replication rate, together with a significant reduction in the rate of beta-cell apoptosis. Hence, it seems possible that GLP-1R activation may be able to enhance beta-cell mass even in the presence of an autoimmune attack, if therapy is initiated before the onset of hyperglycemia. Ex-4 has also been administered to NOD mice alone or in combination with different immune modulators, lisofylline [98], antilymphocyte serum [99], or anti-CD3 immunotherapy [100]: the highest frequency of diabetes remission was observed in animals that received the combination treatments, suggesting a beneficial synergistic effect between immunomodulators and the Ex-4 regenerative agent. Furthermore, recent studies have reported that increasing the levels of circulating GLP-1 by inhibiting dipeptidyl peptidase-4 results in prolonged islet graft survival and decreased insulitis in diabetic NOD mice [101], that Ex-4 in vitro decreased IFN-γ-induced expression of several inflammatory mediators in human islets and MIN6 cells [102] and that Ex-4 in vivo induced a recovery of beta-cell proliferation during the initial stages of insulitis in the BB/Worcester rat [103]. The finding of an anti-inflammatory action of Ex-4 may have implications for the treatment of both types of diabetes, since the presence of immune cells in islets from human T2D diabetic patients and from animal models of T2D has been reported [96].

6.4. No Reliable Method to Assess Beta-Cell Mass in Patients Receiving GLP-1R Agonist Supplementation. Among the demonstrated biological actions of GLP-1R agonists, none has generated more interest than the findings of enhanced beta-cell growth and survival in rodent diabetic models [104]. The possibility that incretin therapy may not only improve beta-cell function but also increase beta-cell mass in patients with T2D has, therefore, created much excitement. Determination of the success of therapeutic strategies designed to enhance beta-cell regeneration requires reliable methods for the assessment of beta-cell mass. In animal models, beta-cell mass can be easily calculated as the product of pancreatic weight and the fractional beta-cell area in cross-sections from different regions of the pancreas. In human, there are no direct measures currently available to determine whether an antidiabetes drug has the ability to alter the course of T2D by increasing beta-cell mass (replication, neogenesis) or attenuating beta-cell apoptosis. Noninvasive imaging techniques that can assess islet mass are currently being explored, but have not yet reached the sensitivity that is required for use in humans, and pancreatic tissue for histological examination cannot be ethically procured for research purposes only. This leaves no direct means for testing direct effects of GLP-1-based drugs on beta-cell mass in diabetic patients.

6.5. Significance of the Islet-Derived GLP-1 Source and Its Modulation by GLP-1R Agonist Supplementation. Beside production and secretion of GLP-1 by the enteroendocrine L cells throughout the intestinal epithelium, there is now growing evidence that under certain conditions, islet alpha-cells are an extraintestinal site for GLP-1 production, perhaps to support the function and/or survival of neighboring beta-cells. While proglucagon is expressed in islet alpha-cells, PC2 is the predominant processing enzyme in these cells, cleaving proglucagon to yield glucagon rather than GLP-1. However, under certain conditions, alpha cells do express PCI/3 and liberate GLP-1 from proglucagon instead. Several models of pancreatic injury have been associated with islet GLP-1 production. Treatment of neonatal rats with STZ increases pancreatic GLP-1 content [105]. STZ treatment of adult rats increases PCI/3 expression in glucagon-immunoreactive cells in islets and increases GLP-1 levels in islets and...
plasma [106]. It has been shown recently that treatment of isolated mouse islets with a PC13-expressing adenovirus induces GLP-1 release from alpha cells, increases GIIS, and promotes islet survival [107]. In addition, transplantation of PC13-expressing alpha-cells increases plasma GLP-1 levels and improves glucose homeostasis in rodent models of type 1 and type 2 diabetes [108]. Thus, manipulation of proglucagon processing in the alpha cell to yield GLP-1 can be viewed as a strategy for enhancing islet function and survival. Since GLP-1 seem to be expressed in islets under certain conditions, it might be necessary to revise our understanding of how this hormone modulates beta-cell secretion and growth. Our current view relies on the network of neural and endocrine signals originating in the gut after food intake that stimulate insulin secretion. We should now also consider the possibility that intraislet GLP-1 signals might modulate insulin secretion and/or influence beta-cell survival. Determining the physiological importance of the islet-derived GLP-1 source during diabetes and its modulation during administration of exogenous GLP-1R agonists is a clinically relevant issue.

Acknowledgment

This work was supported in part by grants from the Centre National de la Recherche Scientifique (CNRS), Servier and Merck-Serono. No potential conflict of interests relevant to this paper was reported.

References

[1] A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, “β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes,” Diabetes, vol. 52, no. 1, pp. 102–110, 2003.

[2] R. P. Robertson, “Successful islet transplantation for patients with diabetes—fact or fantasy?” The New England Journal of Medicine, vol. 343, no. 4, pp. 289–290, 2000.

[3] M. Salehi, B. A. Aulinger, and D. A. D’Alessio, “Targeting β-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins,” Endocrine Reviews, vol. 29, no. 3, pp. 367–379, 2008.

[4] J. J. Meier, A. E. Butler, R. Galasso, R. A. Rizza, and P. C. Butler, “Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans,” Diabetologia, vol. 49, no. 11, pp. 2689–2696, 2006.

[5] J. J. Meier, J. C. Lin, A. E. Butler, R. Galasso, D. S. Martinez, and P. C. Butler, “Direct evidence of attempted beta cell regeneration in an 89-year-old patient with recent-onset type 1 diabetes,” Diabetologia, vol. 49, no. 8, pp. 1838–1844, 2006.

[6] L. Tillmar, C. Carlsson, and N. Welsh, “Control of insulin mRNA stability in rat pancreatic islets: regulatory role of a 3’-untranslated region pyrimidine-rich sequence,” Journal of Biological Chemistry, vol. 277, no. 2, pp. 1099–1106, 2002.

[7] K. P. Knoch, R. Meisterfeld, S. Kersting et al., “CAMP-dependent phosphorylation of PKB promotes the expression of insulin secretory granule proteins in β cells,” Cell Metabolism, vol. 3, no. 2, pp. 123–134, 2006.

[8] D. J. Drucker, J. Philippe, S. Mojsow, W. L. Chick, and J. F. Habener, “Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line,” Proceedings of the National Academy of Sciences USA, vol. 84, pp. 3434–3438, 1987.

[9] X. Wang, C. M. Cahill, M. A. Pineyro, J. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells,” Endocrinology, vol. 140, no. 10, pp. 4904–4907, 1999.

[10] X. Wang, J. Zhou, M. E. Doyle, and J. M. Egan, “Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism,” Endocrinology, vol. 142, no. 5, pp. 1820–1827, 2001.

[11] D. A. Stoffers, T. J. Kieffer, M. A. Hussain et al., “Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas,” Diabetes, vol. 49, no. 5, pp. 741–748, 2000.

[12] H. Ohlsson, K. Karlsson, and T. Edlund, “IPF1, a homeodomain-containing transactivator of the insulin gene,” The EMBO Journal, vol. 12, no. 11, pp. 4251–4259, 1993.

[13] J. Le Lay and R. Stein, “Involvement of PDX-1 in activation of human insulin gene transcription,” Journal of Endocrinology, vol. 188, no. 2, pp. 287–294, 2006.

[14] T. Kitamura, J. Nakae, Y. Kitamura et al., “The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic β cell growth,” Journal of Clinical Investigation, vol. 110, no. 12, pp. 1839–1847, 2002.

[15] J. Buteau, M. L. Spatz, and D. Accili, “Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass,” Diabetes, vol. 55, no. 5, pp. 1190–1196, 2006.

[16] G. Skoglund, M. A. Hussain, and G. G. Holz, “Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene CAMP response element,” Diabetes, vol. 49, no. 7, pp. 1156–1164, 2000.

[17] O. G. Chepurny, M. A. Hussain, and G. G. Holz, “Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220,” Endocrinology, vol. 143, no. 6, pp. 2303–2313, 2002.

[18] P. E. Light, J. E. Manning Fox, M. J. Riedel, and M. B. Wheeler, “Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism,” Molecular Endocrinology, vol. 16, no. 9, pp. 2135–2144, 2002.

[19] J. Gromada, J. J. Holst, and P. Rorsman, “Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1,” Pflugers Archiv European Journal of Physiology, vol. 435, no. 5, pp. 583–594, 1998.

[20] M. Nakazaki, A. Crane, M. Hu et al., “cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets,” Diabetes, vol. 51, no. 12, pp. 3440–3449, 2002.

[21] C. Shiota, O. Larsson, K. D. Shelton et al., “Sulphonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose,” Journal of Biological Chemistry, vol. 277, no. 40, pp. 37176–37183, 2002.

[22] J. De Rooij, F. J. T. Wartkruis, M. H. G. Verheijen et al., “Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP,” Nature, vol. 396, no. 6710, pp. 474–477, 1998.
[23] H. Kawasaki, G. M. Springett, N. Mochizuki et al., “A family of cAMP-binding proteins that directly activate Rap1,” Science, vol. 282, no. 5397, pp. 2275–2279, 1998.

[24] T. Shibasaki, Y. Sunaga, and S. Seino, “Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis,” Diabetes, vol. 53, no. 3, pp. S59–S62, 2004.

[25] G. Kang, O. G. Chepurny, B. Malester et al., “cAMP sensor P.E. MacDonald, X. Wang, F. Xia et al., “Antagonism of rat β-cell voltage-dependent K’ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways,” Journal of Biological Chemistry, vol. 278, no. 52, pp. 52446–52453, 2003.

[26] N. Sonoda, T. Imamura, T. Yoshizaki, J. L. Babendure, J. G. Kang, O. G. Chepurny, B. Malester et al., “cAMP sensor 

[27] T. Tsuibo, G. da Silva Xavier, G. G. Holz, L. S. Jouaville, A. P. Thomas, and G. A. Rutter, “Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 β-cells,” Biochemical Journal, vol. 369, no. 2, pp. 287–299, 2003.

[28] T. Ishibashi, Y. Nakamura, M. Joshi, S. Takenaka, and H. Okamoto, “CD38 disruption impairs glucose- and exocytosis in pancreatic β-cells,” Diabetes, vol. 56, no. 3, pp. 6614–6619, 2008.

[29] L. D. C. Fraser, S. J. Tavalin, L. B. Lester et al., “A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events,” The EMBO Journal, vol. 17, no. 8, pp. 2261–2272, 1998.

[30] T. J. Hulme, T. C. Lin, R. E. Westenbrook, T. Scheuer, and W. A. Catterall, “β-adrenergic regulation requires direct anchoring of PKA to cardiac Ca1.2 channels via a leucine zipper interaction with A-kinase-anchoring protein 15,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 22, pp. 13093–13098, 2003.

[31] G. Kang, J. W. Joseph, O. G. Chepurny et al., “Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic β-cells,” Journal of Biological Chemistry, vol. 278, no. 10, pp. 8279–8285, 2003.

[32] T. Tsuboi, G. da Silva Xavier, G. G. Holz, L. S. Jouaville, A. P. Thomas, and G. A. Rutter, “Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 β-cells,” Biochemical Journal, vol. 369, no. 2, pp. 287–299, 2003.

[33] B. J. Kim, K. H. Park, C. Y. Yim et al., “Generation of nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose by glucagon-like peptide-1 evokes Ca2+ signal that is essential for insulin secretion in mouse pancreatic islets,” Diabetes, vol. 57, no. 4, pp. 868–878, 2008.

[34] I. Kato, Y. Yamamoto, M. Fujimura, N. Noguchi, S. Takeda, and H. Okamoto, “CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, [Ca2+]i, and insulin secretion,” Journal of Biological Chemistry, vol. 274, no. 4, pp. 1869–1872, 1999.

[35] L. B. Lester, M. C. Faux, J. B. Nauert, and J. D. Scott, “Targeted protein kinase A and P2B regulate insulin secretion through reversible phosphorylation,” Endocrinology, vol. 142, no. 3, pp. 1218–1227, 2001.

[36] G. Lohart, S. Schoch, P. S. Kaeser, C. J. Larkin, T. C. Sudhof, and D. J. Linden, “Phosphorylation of RIM1δ by PKA triggers presynaptic long-term potentiation at cerebellar parallel fiber synapses,” Cell, vol. 115, no. 1, pp. 49–60, 2003.

[37] Y. Wang, M. Okamoto, F. Schmitz, K. Hofmann, and T. C. Sudhof, “Rim is a putative rab3 effector in regulating synaptic-vesicle fusion,” Nature, vol. 388, no. 6642, pp. 593–598, 1997.

[38] A. Betz, P. Thakur, H. J. Junge et al., “Functional interaction of the active zone proteins Munc13-1 and RIM1 in synaptic vesicle priming,” Neuron, vol. 30, no. 1, pp. 183–196, 2001.

[39] N. Ozaki, T. Shibasaki, Y. Kashiama et al., “cAMP-GEFII is a direct target of cAMP in regulated exocytosis,” Nature Cell Biology, vol. 2, no. 11, pp. 805–811, 2000.

[40] E. P. Kwan, L. Xie, L. Sheu, T. Ohtsuka, and H. Y. Gaisano, “Interaction between Munc13-1 and RIM is critical for glucagon-like peptide-1-mediated rescue of exocytotic defects in Munc13-1-deficient pancreatic β-cells,” Diabetes, vol. 56, no. 10, pp. 2579–2588, 2007.

[41] K. Fujimoto, T. Shibasaki, N. Yokoi et al., “Piccolo, a Ca2+ sensor in pancreatic β-cells: involvement of cAMP-GEFII-Rim2-Piccolo complex in cAMP-dependent exocytosis,” Journal of Biological Chemistry, vol. 277, no. 52, pp. 50497–50502, 2002.

[42] D. G. Pipeleers, F. C. Schuit, and P. A. In’t Veld, “Interplay of nutrients and hormones in the regulation of insulin release,” Endocrinology, vol. 117, no. 3, pp. 824–833, 1985.

[43] M. Cornu, H. Modi, D. Kawamori, R. N. Kulkarni, M. Joffraud, and B. Thorens, “Glucagon-like peptide-1 increases β-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression,” Journal of Biological Chemistry, vol. 285, no. 14, pp. 10538–10545, 2010.

[44] G. G. Holz, W. M. Kuhreiber, and J. F. Habener, “Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37),” Nature, vol. 361, no. 6410, pp. 362–365, 1993.

[45] M.-L. Peyot, J. P. Gray, J. Lamontagne et al., “Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic β-cells,” PLoS One, vol. 4, no. 7, Article ID e6221, 2009.

[46] B. Portha, G. Lacraz, M. Kergoat et al., “The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes?” Molecular and Cellular Endocrinology, vol. 297, no. 1–2, pp. 73–85, 2009.

[47] M. Dolz, J. Movassat, M. Fradet et al., “cAMP-secretion coupling is impaired in the diabetic GK/par beta-cells. A defect counteracted by GLP-1,” submitted.

[48] N. Dachicourt, P. Serradas, D. Bailbé, M. Kergoat, L. Doaré, and B. Portha, “Glucagon-like peptide-1(7–36)-amide confers glucose sensitivity to previously glucose-incompetent β-cells in diabetic rats: in vivo and in vitro studies,” Journal of Endocrinology, vol. 155, no. 2, pp. 369–376, 1997.

[49] J. Buteau, S. Foisy, E. Joly, and M. Pretkki, “Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor,” Diabetes, vol. 52, no. 1, pp. 124–132, 2003.

[50] D. J. Drucker, “Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis,” Molecular Endocrinology, vol. 17, no. 2, pp. 161–171, 2003.

[51] Y. Li, X. Cao, L. X. Li, P. L. Brubaker, H. Edlund, and D. J. Drucker, “β-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1,” Diabetes, vol. 54, no. 2, pp. 482–491, 2005.
[52] A. Trümper, K. Trümper, and D. Hörisch, "Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β(INS-1)-cells," Journal of Endocrinology, vol. 174, no. 2, pp. 233–246, 2002.

[53] J. Buteau, S. Foisy, C. J. Rhodes, L. Carpenter, T. J. Biden, and M. Prentki, "Protein kinase C activation mediates glucagon-like peptide-1—induced pancreatic β-cell proliferation," Diabetes, vol. 50, no. 10, pp. 2237–2243, 2001.

[54] J. Buteau, R. Roduit, S. Susini, and M. Prentki, "Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells," Diabetologia, vol. 42, no. 7, pp. 856–864, 1999.

[55] C. Demeterco, G. M. Beattie, S. A. Dib, A. D. Lopez, and A. Hayek, "A role for activin A and betacellulin in human fetal pancreatic cell differentiation and growth," Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 10, pp. 3892–3897, 2000.

[56] J. Movassat, G. M. Beattie, A. D. Lopez, and A. Hayek, "Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells," Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 10, pp. 4775–4781, 2002.

[57] T. Xie, M. Chen, Q.-H. Zhang, Z. Ma, and L. S. Weinstein, "β cell-specific deficiency of the stimulatory G protein α-subunit Gsa leads to reduced β cell mass and insulin-deficient diabetes," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 19601–19606, 2007.

[58] U. S. Jhala, G. Canettieri, R. A. Screaton et al., "cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2," Genes and Development, vol. 17, no. 13, pp. 1573–1580, 2003.

[59] B. N. Friedrichsen, N. Neubauer, Y. C. Lee et al., "Stimulation of pancreatic β-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways," Journal of Endocrinology, vol. 188, no. 3, pp. 481–492, 2006.

[60] M.-J. Kim, J.-H. Kang, Y. G. Park et al., "Exendin-4 induction of cyclin D1 expression in INS-1 β-cells: involvement of cAMP-responsive element," Journal of Endocrinology, vol. 188, no. 3, pp. 623–633, 2006.

[61] R. Lupi, R. Mancarella, S. Del Guerra et al., "Effects of exendin-4 on islets from type 2 diabetes patients," Diabetes, Obesity and Metabolism, vol. 10, no. 6, pp. 515–519, 2008.

[62] Z. Liu and J. F. Habener, "Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation," Journal of Biological Chemistry, vol. 283, no. 13, pp. 8723–8735, 2008.

[63] K. Tanabe, Z. Liu, S. Patel et al., "Genetic deficiency of glycolate synthase kinase-3beta corrects diabetes in mouse models of insulin resistance.," PLoS Biology, vol. 6, no. 2, article e37, 2008.

[64] F. Figgeac, B. Uzan, M. Faro, N. Chelali, B. Portha, and J. Mvassatt, "Neonatal growth and regeneration of β-cells are regulated by the Wnt/β-catenin signaling in normal and diabetic rats," American Journal of Physiology, vol. 298, no. 2, pp. E245–E256, 2010.

[65] L. Farilla, H. Hongxiang, C. Bertolotto et al., "Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats," Endocrinology, vol. 143, no. 11, pp. 4397–4408, 2002.

[66] W. Kim and J. M. Egan, "The role of incretins in glucose homeostasis and diabetes treatment," Pharmacological Reviews, vol. 60, no. 4, pp. 470–512, 2008.

[67] Y. Li, T. Hansotia, B. Yusta, F. Ris, P. A. Halban, and D. J. Druecker, "Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis," Journal of Biological Chemistry, vol. 278, no. 1, pp. 471–478, 2003.

[68] B. Yusta, L. L. Baggio, J. L. Estall et al., "GLP-1 receptor activation improves β cell function and survival following induction of endoplasmic reticulum stress," Cell Metabolism, vol. 4, no. 5, pp. 391–406, 2006.

[69] S. Tsunekawa, N. Yamamoto, K. Tsukamoto et al., "Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies," Journal of Endocrinology, vol. 193, no. 1, pp. 65–74, 2007.

[70] J. Buteau, W. El-Assaad, C. J. Rhodes, L. Mosenberg, E. Joly, and M. Prentki, "Glucagon-like peptide-1 prevents beta cell glucolipotoxicity," Diabetologia, vol. 47, no. 5, pp. 806–815, 2004.

[71] M. Ferdaoussi, S. Abdeli, J. Y. Yang et al., "Exendin-4 protects β-cells from interleukin-1β-induced apoptosis by interfering with the c-Jun NH-terminal kinase pathway," Diabetes, vol. 57, no. 5, pp. 1205–1215, 2008.

[72] M. Blandino-Rosano, G. Perez-Arana, J. M. Mellado-Gil, C. Segundo, and M. Aguilar-Diosdado, "Anti-proliferative effect of pro-inflammatory cytokines in cultured β cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1," Journal of Molecular Endocrinology, vol. 41, no. 1–2, pp. 35–44, 2008.

[73] D. Tornhave, P. Kristensen, J. Roser, L. B. Knudsen, and R. S. Heller, "Expression of the GLP-1 receptor in mouse, rat, and human pancreas," Journal of Histochemistry and Cytochemistry, vol. 56, no. 9, pp. 841–851, 2008.

[74] G. Xu, H. Kaneto, M. D. Lopez-Avalos, G. C. Weir, and S. Bonner-Weir, "GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts," Diabetes Research and Clinical Practice, vol. 73, no. 1, pp. 107–110, 2006.

[75] J. Zhou, C. Montrose-Rafizadeh, A. M. Janczewski et al., "Glucagon-like peptide-1 does not mediate amylose release from AR42J cells," Journal of Cellular Physiology, vol. 181, no. 3, pp. 470–478, 1999.

[76] J. Zhou, X. Wang, M. A. Pineyro, and J. M. Egan, "Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells," Diabetes, vol. 48, no. 12, pp. 3258–3266, 1999.

[77] K. H. Yew, M. Hembree, K. Prasad et al., "Cross-talk between bone morphogenetic protein and transforming growth factor-β signaling is essential for exendin-4-induced insulin-positive differentiation of AR42J cells," Journal of Biological Chemistry, vol. 280, no. 37, pp. 32209–32217, 2005.

[78] E. Téi, S. Mehta, S. T. Tulchan et al., "Synergistic endocrine induction by GLP-1 and TGF-β in the developing pancreas," Pancreas, vol. 31, no. 2, pp. 138–141, 2005.

[79] H. Mashima, H. Ohnishi, K. Wakabayashi et al., "Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells," Journal of Clinical Investigation, vol. 97, no. 7, pp. 1647–1654, 1996.

[80] J. Zhou, M. A. Pineyro, X. Wang, M. E. Doyle, and J. M. Egan, "Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3β transcription factors," Journal of Cellular Physiology, vol. 192, no. 3, pp. 304–314, 2002.
[81] H. Hui, C. Wright, and R. Perfetti, “Glucagon-like peptide 1
induces differentiation of islet duodenal homebox-1-
positive pancreatic ductal cells into insulin-secreting cells,”
Diabetes, vol. 50, no. 4, pp. 785–796, 2001.

[82] B. Rolin, M. O. Larsen, C. F. Gottfredsen et al., “The long-
acting GLP-1 derivative NN2211 ameliorates glycemia and
increases β-cell mass in diabetic mice,” American Journal of
Physiology, vol. 283, no. 4, pp. E745–E752, 2002.

[83] C. Tournel, D. Bailhé, M. J. Meile, M. Kergoat, and B. Portha,
“Glucagon-like peptide-1 and exendin-4 stimulate β-cell
neogenesis in streptozotocin-treated newborn rats resulting
in persistently improved glucose homeostasis at adult age,”
Diabetes, vol. 50, no. 7, pp. 1562–1570, 2001.

[84] C. Tournel, D. Bailhé, M. Lacorne, M.-J. Meile, M. Kergoat,
and B. Portha, “Persistent improvement of type 2 diabetes in
the Goto-Kakizaki rat model by expansion of the β-cell mass
during the prediabetic period with glucagon-like peptide-
1 or exendin-4,” Diabetes, vol. 51, no. 5, pp. 1443–1452,
2002.

[85] Q. Wang and P. Brubaker, “Glucagon-like peptide-1 treat-
mant delays the onset of diabetes in 8-week-old db/db mice,”
Diabetologia, vol. 45, no. 9, pp. 1263–1273, 2002.

[86] G. Xu, D. A. Stoffers, J. F. Habener, and S. Bonner-Weir,
“Exendin-4 stimulates both β-cell replication and neogenesis,
resulting in increased β-cell mass and improved glucose
tolerance in diabetic rats,” Diabetes, vol. 48, no. 12, pp. 2270–
2276, 1999.

[87] D. A. Stoffers, B. M. Desai, D. D. DeLeon, and R. A. Simmons,
“Neonatal exendin-4 prevents the development of diabetes in
the intrauterine growth retarded rat,” Diabetes, vol. 52, no. 3,
pp. 734–740, 2003.

[88] J. M. Egan, A. Bulotta, H. Hui, and R. Perfetti, “GLP-1
receptor agonists are growth and differentiation factors for
pancreatic islet beta cells,” Diabetes/Metabolism Research and
Reviews, vol. 19, no. 2, pp. 115–123, 2003.

[89] S. Klinger, C. Poussin, M. B. Debril, W. Doké, P. A. Halban,
and B. Thorens, “Increasing GLP-1-induced β-cell proliferation
by silencing the negative regulators of signaling cAMP
response element modulator-α and DUSP14,” Diabetes, vol.
57, no. 3, pp. 584–593, 2008.

[90] S. R. Ahmad and J. Swann, “Exenatide and rare adverse
events,” The New England Journal of Medicine, vol. 358, no.
18, pp. 1970–1971, 2008.

[91] J. A. Koehler, L. L. Baggio, B. J. Lamont, S. Ali, and
D. J. Drucker, “Glucagon-like peptide-1 receptor activation
modulates pancreatitis-associated gene expression but does
not modify the susceptibility to experimental pancreatitis in
mice,” Diabetes, vol. 58, no. 9, pp. 2148–2161, 2009.

[92] D. D. Dore, J. D. Seeger, and K. A. Chan, “Use of a claims-
based active drug safety surveillance system to assess the risk
of acute pancreatitis with exenatide or sitagliptin compared
to metformin or glyburide,” Current Medical Research and
Opinion, vol. 25, no. 4, pp. 1019–1027, 2009.

[93] A. V. Matveyenko, S. Dry, H. I. Cox et al., “Beneficial endocrine
but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide
transgenic rat model of type 2 diabetes: interactions with metformin,” Diabetes, vol.
58, no. 7, pp. 1604–1615, 2009.

[94] J. S. Nachmani, D. G. Bulchandani, A. Nookala et al., “Bio-
chemical and histological effects of exendin-4 (exenatide) on
the rat pancreas,” Diabetologia, vol. 53, no. 1, pp. 153–159,
2010.

[95] A. E. Butler, R. Galasso, A. Matveyenko, R. A. Rizza, S. Dry,
and P. C. Butler, “Pancreatic duct replication is increased with
obesity and type 2 diabetes in humans,” Diabetologia, vol. 53,
no. 1, pp. 21–26, 2010.

[96] M. Y. Donath, D. M. Schumann, M. Faulenbach, H. Ellings-
gaard, A. Perren, and J. A. Ehes, “Islet inflammation in type
2 diabetes: from metabolic stress to therapy,” Diabetes care,
vol. 31, supplement 2, pp. S161–S164, 2008.

[97] J. Zhang, Y. Tokui, K. Yamagata et al., “Continuous stimu-
lization of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1
diabetes,” Diabetologia, vol. 50, no. 9, pp. 1900–1909, 2007.

[98] Z. Yang, M. Chen, J. D. Carter et al., “Combined treatment
with lisofylline and exendin-4 reverses autoimmune diabetes,”
Biochemical and Biophysical Research Communications,
vol. 344, no. 3, pp. 1017–1022, 2006.

[99] N. Ogawa, J. F. List, J. F. Habener, and T. Maki, “Cure of
ovet diabetes in NOD mice by transient treatment with anti-
lymphocyte serum and exendin-4,” Diabetes, vol. 53, no. 7,
pp. 1700–1705, 2004.

[100] N. A. Sherry, W. Chen, J. A. Kushner et al., “Exendin-4
improves reversal of diabetes in NOD mice treated with anti-
CD3 monoclonal antibody by enhancing recovery of β-cells,”
Endocrinology, vol. 148, no. 11, pp. 5136–5144, 2007.

[101] S. J. Kim, C. Nian, D. J. Doudet, and C. H. S. McIntosh,
“Dipeptidyl peptidase IV inhibition with MK0431 improves
islet graft survival in diabetic NOD mice partially via T-cell
modulation,” Diabetes, vol. 58, no. 3, pp. 641–651, 2009.

[102] U. Pugazhenthi, K. Velmurugan, A. Tran, G. Mahaffey,
and S. Pugazhenthi, “Anti-inflammatory action of exendin-4 in
human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients,” Diabetolo-
gia, vol. 53, no. 11, pp. 2357–2368, 2010.

[103] G. Pérez-Arana, M. Blandino-Rosano, A. Prada-Oliveira, M.
Aguilar-Diosdado, and C. Segundo, “Decrease in β-cell pro-
iferation precedes apoptosis during diabetes development
in bio-breeding/worcester rat: beneficial role of exendin-4,”
Endocrinology, vol. 151, no. 6, pp. 2538–2546, 2010.

[104] P. L. Brubaker and D. J. Drucker, “Minireview: glucagon-
like peptides regulate cell proliferation and apoptosis in the
pancreas, gut, and central nervous system,” Endocrinology,
vol. 145, no. 6, pp. 2653–2659, 2004.

[105] S. Thyssen, E. Arany, and D. J. Hill, “Ontogeny of regen-
eration of β-cells in the neonatal rat after treatment with streptozotocin,” Endocrinology,
vol. 147, no. 5, pp. 2346–
2356, 2006.

[106] Y. Nie, M. Nakashima, P. L. Brubaker et al., “Regulation of
pancreatic PC1 and PC2 associated with increased glucagon-
like peptide 1 in diabetic rats,” Journal of Clinical Investiga-
tion, vol. 105, no. 7, pp. 955–965, 2000.

[107] R. D. Wideman, I. L. Y. Yu, T. D. Webber et al., “Improving
function and survival of pancreatic islets by endogenous
production of glucagon-like peptide 1 (GLP-1),” Proceedings
of the National Academy of Sciences of the United States
of America, vol. 103, no. 36, pp. 13468–13473, 2006.

[108] R. D. Wideman, S. D. Covey, G. C. Webb, D. J. Drucker,
and T. J. Kieffer, “A switch from prohormone convertase (PC)-2 to
PC1/3 expression in transplanted α-cells is accompanied by
differential processing of proglucagon and improved glucose
homeostasis in mice,” Diabetes, vol. 56, no. 11, pp. 2744–
2752, 2007.